Search

Serelaxin

bones come together).It is a heterodimer protein secreted by the corpus luteum and placenta during pregnancy. … Recombinant human relaxin is a hormone produced during pregnancy that facilitates the birth process by causing a softening and lengthening of the cervix and the pubic symphysis (the place where the pubic

AN-9

Pivaloyloxymethyl butyrate (AN-9), an acyloxyalkyl ester prodrug of butyric acid (BA), exhibited low toxicity and significant anticancer activity in vitro and in vivo. It shows greater potency than BA at inducing malignant cell different...

Tetrahydrofolic acid

Tetrahydrofolic acid is a folic acid derivative that is produced from dihydrofolic acid after conversion by dihydrofolate reductase. … It is converted into 5,10-methylenetetrahydrofolate by serine hydroxymethyltransferase. It is a soluble coenzyme in many reactions, especially in the metabolism of amino acids and nucleic acids.

Saredutant

Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.

Fucoxanthin

, but the exact mechanism of anti-cancer action of fucoxanthin is not fully elucidated. … Fucoxanthin causes antitumor and anticarcinogenic effects by inducing G1 cell-cycle arrest and apoptosis by modulating expression of various cellular molecules and cellular signal transduction pathways

Linaclotide

Linaclotide was first approved by the FDA on August 30, 2012.[A260271] It gained EMA and Health Canada approval on November 26, 2012 [L47216] and December 3, 2013,[L47221] respectively.

Razuprotafib

Razuprotafib, also known as AKB-9778, is a small-molecule inhibitor restoring Tie2 activation by inhibiting VE-PTP. … [L27171,L27176] In investigations against diabetes and COVID-19, razuprotafib is self-administered by patients through subcutaneous injection.

Emricasan

Emricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA. … It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis.

Lemuteporfin

Lemuteporfin, under development by QLT Incorporated, is a benzoporphyrin-derived chlorin-like photosensitizer. It is intended for the treatment of beign prostatic hyperplasia.

Sumanirole